Literature DB >> 18582445

Induction of ketosis may improve mitochondrial function and decrease steady-state amyloid-beta precursor protein (APP) levels in the aged dog.

Christa M Studzinski1, William A MacKay, Tina L Beckett, Samuel T Henderson, M Paul Murphy, Patrick G Sullivan, W McIntyre Burnham.   

Abstract

Region specific declines in the cerebral glucose metabolism are an early and progressive feature of Alzheimer's disease (AD). Such declines occur pre-symptomatically and offer a potential point of intervention in developing AD therapeutics. Medium chain triglycerides (MCTs), which are rapidly converted to ketone bodies, were tested for their ability to provide an alternate energy source to neurons suffering from compromised glucose metabolism. The present study determined the short-term effects of ketosis in aged dogs, a natural model of amyloidosis. The animals were administered a 2 g/kg/day dose of MCTs for 2 months. Mitochondrial function and oxidative damage assays were then conducted on the frontal and parietal lobes. Amyloid-beta (Abeta), amyloid precursor protein (APP) processing and beta-site APP cleaving enzyme (BACE1) assays were conducted on the frontal, parietal and occipital lobes. Aged dogs receiving MCTs, as compared to age-matched controls, showed dramatically improved mitochondrial function, as evidenced by increased active respiration rates. This effect was most prominent in the parietal lobe. The improved mitochondrial function may have been due to a decrease in oxidative damage, which was limited to the mitochondrial fraction. Steady-state APP levels were also decreased in the parietal lobe after short-term MCT administration. Finally, there was a trend towards a decrease in total Abeta levels in the parietal lobe. BACE1 levels remained unchanged. Combined, these findings suggest that short-term MCT administration improves energy metabolism and decreases APP levels in the aged dog brain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582445     DOI: 10.1016/j.brainres.2008.06.005

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  30 in total

Review 1.  Brain fuel metabolism, aging, and Alzheimer's disease.

Authors:  Stephen Cunnane; Scott Nugent; Maggie Roy; Alexandre Courchesne-Loyer; Etienne Croteau; Sébastien Tremblay; Alex Castellano; Fabien Pifferi; Christian Bocti; Nancy Paquet; Hadi Begdouri; M'hamed Bentourkia; Eric Turcotte; Michèle Allard; Pascale Barberger-Gateau; Tamas Fulop; Stanley I Rapoport
Journal:  Nutrition       Date:  2010-10-29       Impact factor: 4.008

2.  A ketogenic diet improves motor performance but does not affect β-amyloid levels in a mouse model of Alzheimer's disease.

Authors:  Tina L Beckett; Christa M Studzinski; Jeffrey N Keller; M Paul Murphy; Dana M Niedowicz
Journal:  Brain Res       Date:  2013-02-12       Impact factor: 3.252

Review 3.  Neuroprotection in metabolism-based therapy.

Authors:  Adam L Hartman
Journal:  Epilepsy Res       Date:  2011-08-26       Impact factor: 3.045

4.  A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6/2 1J mouse model of Huntington's disease.

Authors:  David N Ruskin; Jessica L Ross; Masahito Kawamura; Tiffany L Ruiz; Jonathan D Geiger; Susan A Masino
Journal:  Physiol Behav       Date:  2011-04-09

5.  Effect of a ketogenic meal on cognitive function in elderly adults: potential for cognitive enhancement.

Authors:  Miho Ota; Junko Matsuo; Ikki Ishida; Kotaro Hattori; Toshiya Teraishi; Hidekazu Tonouchi; Kinya Ashida; Takeshi Takahashi; Hiroshi Kunugi
Journal:  Psychopharmacology (Berl)       Date:  2016-08-27       Impact factor: 4.530

6.  Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; Lauren C Costantini
Journal:  Nutr Metab (Lond)       Date:  2009-08-10       Impact factor: 4.169

7.  Proteogenomics of synaptosomal mitochondrial oxidative stress.

Authors:  James M Flynn; Gregg A Czerwieniec; Sung W Choi; Nicholas U Day; Bradford W Gibson; Alan Hubbard; Simon Melov
Journal:  Free Radic Biol Med       Date:  2012-07-13       Impact factor: 7.376

Review 8.  Ketogenic Diets for Adult Neurological Disorders.

Authors:  Tanya J W McDonald; Mackenzie C Cervenka
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

9.  Dietary enrichment with medium chain triglycerides (AC-1203) elevates polyunsaturated fatty acids in the parietal cortex of aged dogs: implications for treating age-related cognitive decline.

Authors:  Ameer Y Taha; Samuel T Henderson; W M Burnham
Journal:  Neurochem Res       Date:  2009-03-20       Impact factor: 3.996

Review 10.  Hypometabolism as a therapeutic target in Alzheimer's disease.

Authors:  Lauren C Costantini; Linda J Barr; Janet L Vogel; Samuel T Henderson
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.